

Yale SCHOOL OF MEDICINE

Chief, Section of Medical Oncology and Hematology, Department of Internal
Medicine and Deputy Director for Clinical Affairs, Yale Cancer Center
Yale School of Medicine
New Haven, Connecticut

THE SEARCH

The Yale Cancer Center (YCC) and the Department of Internal Medicine at the Yale School of Medicine (YSM) seek a nationally recognized, dynamic, and visionary leader to become the Section Chief of Medical Oncology and Hematology in the Department of Internal Medicine and the Deputy Director for Clinical Affairs at the YCC. As the leader of one of the largest and most complex sections within the Department of Medicine, the Section Chief of Medical Oncology and Hematology is responsible for academic advancement, mentorship, and career development of the faculty. As the Deputy Director for Clinical Affairs at the YCC, they will support and engage clinicians across multiple specialties and multiple sites. These critical roles bridge clinical excellence, research innovation, and faculty development at one of the nation's most storied academic medical centers and is a transformative opportunity to lead at a premier institution where world-class science meets a rapidly expanding clinical enterprise.

For more than 50 years, the Yale Cancer Center has been Connecticut's only NCI-designated Comprehensive Cancer Center and one of only three in New England. It notably brings together both inpatient and outpatient care in one hospital on the main campus while also having 13 other locations in the state of Connecticut and Rhode Island for care delivery. All of these sites are staffed exclusively by Yale faculty in the section of Medical Oncology and Hematology. The YCC leverages the resources of both the school and the hospital to advance research, prevention, and patient care. The center's mission is to conduct research, develop therapies, and provide patient care by integrating the expertise of physicians, nurses, and scientists from both the school and the hospital.

Cancer research at Yale began decades before the YCC was founded, when the first use of chemotherapy, nitrogen mustard, was administered at Yale New Haven Hospital (YNHH) in 1942. Since that first use of chemotherapy, research efforts have expanded to include three Specialized Program of Research Excellence (SPORE) grants in lung cancer, head and neck cancer, and skin cancer, and about 100 NCI-funded research projects. With the development of a CAR T-Cell Therapy Program, and a Phase I Program that offers over 40 Phase I trials to patients, YCC has become a world leader in cancer care, research, and education, delivering transformative scientific discoveries and care innovations to patients.

The Section of Medical Oncology and Hematology oversees close to 130 faculty members – including clinical faculty, clinical trialists, physician-scientists, and research scientists located at multiple sites across the Yale New Haven Health System – and a thriving Medical Oncology-Hematology fellowship program recruiting ten fellows each year. Members of the Section deliver cancer care and treat nearly 48% of the state’s cancer patients, offering 13 disease-specific centers of excellence and a network of 14 care locations across Connecticut and Rhode Island. This statewide system provides the opportunity to pioneer innovative approaches across diverse communities and in a variety of different clinical settings. The faculty have a broad range of expertise in carrying out bench-to-bedside research, leading clinical trials, providing care to patients and survivors impacted by all cancer types, and educating the next generation of physicians and researchers.

The Section Chief of Medical Oncology and Hematology partners closely with clinical and operational leaders across YSM, YCC, and Smilow Cancer Hospital. Reporting to the [Director of the YCC](#) and the [Chair of Internal Medicine](#), the Section Chief will be a respected physician and successful researcher who has a deep commitment to the tripartite mission, inclusive of optimizing clinical care; supporting discovery, translational, clinical, and health services research; mentoring faculty and fellows; and guiding administrative, budgetary, and philanthropic efforts. This position offers an opportunity to strengthen the alignment of the academic mission with clinical growth in a growing statewide health system. The Section Chief will be a transparent, collaborative, and creative leader who will be a champion for innovation, have an inclusive leadership mindset, and have a passion for engaging multidisciplinary teams in a matrixed environment. This leader will exemplify and encourage a culture of inclusivity, mentorship, and professional development; have a team-based approach; and recruit highly qualified faculty, staff, and trainees.

An MD, DO, or MD/PhD, with board certification in medical oncology and/or hematology, is required. The successful candidate will have a record commensurate with appointment at the rank of full professor in the Department of Internal Medicine and the School of Medicine. The Yale School of Medicine has retained Isaacson, Miller, a national executive search firm, to assist with this search. Inquiries, nominations, and applications should be directed in confidence to the firm as indicated at the end of this document. *For more information on the Yale School of Medicine, Yale New Haven Health, the Department of Internal Medicine, and the Yale Cancer Center and Smilow Cancer Hospital, please visit the appendix.*

ABOUT THE SECTION OF MEDICAL ONCOLOGY AND HEMATOLOGY

With approximately 130 faculty members, the [Section of Medical Oncology and Hematology](#) is one of the largest and most complex sections in the [Department of Internal Medicine](#). The Section includes both medical oncology and hematology (benign and malignant). The Section has a dual role in that it upholds both the academic mission and the clinical mission, delivering high-quality cancer care across Yale New Haven Health and Smilow Cancer Hospital’s statewide network.

The Section of Medical Oncology and Hematology is fully integrated into the Yale Cancer Center's organizational structure, comprising divisions that span disease-specific, therapeutic, and research units. The disease-specific divisions include Breast Oncology, Gastrointestinal Oncology, Genitourinary Cancers, Thoracic Oncology, Hematologic Malignancies, Head & Neck Cancers/Sarcoma, Neuro-Oncology, Skin & Kidney Disease, and Classical Hematology. Other divisions include the Center for Molecular and Cellular Oncology (CMCO), Clinical Genetics, Palliative Care, Experimental Therapeutics, and Translational Hematology. The clinical work of these divisions supports a large network of Smilow Cancer Hospital sites across Connecticut and Rhode Island and requires close collaboration with surgical oncology, radiation oncology, pathology, and other specialties.

Research in the Section spans basic, translational, clinical, and health services research with a strong translational and clinical portfolio, including SPORE grants and investigator-initiated trials. Research programs in medical oncology are fully integrated with the research programs in the YCC, particularly the [Developmental Therapeutics Research Program](#), [Cancer Immunology](#), and [Cancer Prevention and Control](#). There is a strong focus on research, both clinical and laboratory, across solid tumors and hematological malignancies. Both the pediatric and adult sickle cell programs are robust clinically and in research, and Yale has an active program in bleeding disorders. In addition to the individual research programs led by medical oncology and hematology faculty, collaborative research projects are ongoing with faculty members of several other departments, including immunology, genetics, pharmacology, laboratory medicine, and pathology who have common research interests.

The Translational Research Office and Translational Incubator facilitate collaboration between the basic scientists across YSM, YCC, and clinicians at Smilow Cancer Hospital, with the goal of bringing promising new therapeutics from the laboratory to patients. There is great emphasis on collaboration with basic science programs and fostering physician-scientist careers.

Supporting the education mission, the [Yale Medical Oncology-Hematology Fellowship Program](#), home to 33 fellows, is a 36-month training program that provides comprehensive clinical training in neoplasia and classical hematology and a robust research experience to prepare fellows for lifelong careers in academic medicine. Each year, the program welcomes ten new trainees, including one fellow through the American Society of Hematology (ASH) Hematology-Focused Fellowship Training Program. The Section also supports medical student and resident education in oncology and hematology.

The Section is academically based in the Department of Internal Medicine, and the Section Chief plays an active role in the Department of Medicine. The clinical work of the Section, as well as clinical trials and all research grants, is housed within the Yale Cancer Center. The relationship between the Department of Medicine and the Cancer Center is a major strength for the Section of Medical Oncology and Hematology and underscores the inherent value of Yale's matrixed system. In FY24, the Section received \$55M in grants and contracts and had an operating budget of \$12M. With a clinical revenue of \$110M in FY24, the Section generates significant clinical revenue and is central to Yale's goal of being a top-tier destination for cancer care and research.

ROLE OF THE SECTION CHIEF

Reporting to the Director of the Yale Cancer Center and the Chair of Internal Medicine, the Section Chief for Medical Oncology and Hematology guides the academic mission of the Section. The clinical Division Chiefs for the disease-specific programs at the Yale Cancer Center report to the Section Chief and Deputy Director. These Division Chiefs oversee clinical operations and both clinical and translational research, and they each provide mentorship and oversight for their faculty. They report to the Section Chief for academic and strategic oversight. The Medical Oncology-Hematology fellowship program director reports to the Section Chief for education mission oversight.

The role operates within a highly integrated and matrixed environment, requiring close collaboration with the Chief Medical Officer and administrative leaders for ambulatory and inpatient services, the Clinical Trials Office leadership and translational research program directors, and the Department of Internal Medicine leadership for academic governance and faculty affairs.

All faculty within Medical Oncology and Hematology ultimately report to the Section Chief for academic matters, including promotion, mentorship, and alignment with institutional goals. The Section Chief plays a critical role in fostering an inclusive, collaborative culture that supports physician-scientists, educators, and clinicians across diverse career tracks.

KEY OPPORTUNITIES AND CHALLENGES

The Section Chief will have strategic oversight of a mission-critical section of the institution at a time of change and evolution, both locally and nationally. The Chief will be an adept manager and creative problem-solver who can inspire a large team through a period of clinical expansion while maintaining excellence in research and educational programs. Playing a vital role in coordinating cancer-related care at YNHH, the next Chief will be an engaged partner to other cancer leaders and YSM leadership, balancing advocacy for the interests of the Section with the needs of YSM and YNHH overall, as the success of each relies on the success of both.

To succeed in this role, the Chief will address several key opportunities and challenges, as detailed below.

Provide strategic leadership that positions Yale as a destination cancer center

The Chief will inspire a clear, ambitious, and cohesive vision for the Section, charting a direction that aligns with the priorities of the YCC, the Department of Internal Medicine, the Smilow Cancer Hospital Yale Medicine, and Yale School of Medicine. The Section operates in a highly matrixed environment with multiple areas of engagement and commitment. It is the charge of the Chief to provide transparent communication about and alignment of the clinical and academic mission of the entities involved and leverage the strong clinical and scientific programs to achieve top rankings nationally. The Chief will be expected to collaborate closely with relevant stakeholders in creating and executing a plan that takes cancer care, research, and education to new heights, with the goal of positioning YCC and the Smilow

Cancer Hospital as a top-tier destination for cancer care and research. The Section Chief will also engage in philanthropic activities, cultivate grateful patient relationships, and build alliances with industry to support innovation and infrastructure in cancer research and care.

Support and enhance a growing statewide system of patient care

The Section is comprised of talented faculty, providers, and staff who provide exceptional and compassionate care to cancer patients at the Smilow Cancer Hospital's clinical sites across Connecticut. Over the past 15 years, Smilow Cancer Hospital, YCC, and Yale Medicine have developed a statewide academic oncology and hematology presence. Initially, this effort involved purchasing several large practices, but over the last 5 years, the emphasis has been on building subspecialty and multidisciplinary care, replete with full access to clinical trials, across the state. Each of the physicians at the network sites is based within a disease-specific division (e.g. breast oncology) and with very few exceptions, all focus primarily on an individual disease. This approach has allowed the Section to deliver outstanding care throughout the state and has led to an increase in accrual to clinical trials.

This Chief role is one that comes with the opportunity to materially impact the health of a state and region through network-wide initiatives to standardize quality, improve patient access to specialized care, and expand clinical trials. The Chief will continue to work within YCC to expand and enhance care delivered throughout the network with an eye toward improving operational efficiency, workforce shortages, clinical trial enrollment, and access to disease-specific expertise across all sites to enhance the academic mission. Connecticut is a microcosm of the United States, and there are significant disparities in cancer care delivery and cancer outcomes related to income variation, race, ethnicity, and education. The YCC and YSM are committed to minimizing inequities in cancer care throughout the region, and the new Section Chief will play a significant role in this effort by partnering with the Associate Director for Community Outreach and Engagement. The Chief will also drive multidisciplinary collaboration by strengthening relationships with surgical oncology, radiation oncology, pathology, and other departments to build cohesive disease-specific programs and integrated care pathways.

Elevate and nurture research excellence

Yale has long been a powerhouse for discovery science, and faculty have a long-standing, impressive track record of advancements in basic, translational, clinical, and health services research. With growth opportunities in research across the basic-clinical continuum, the Section Chief will nurture a strong culture of communication and cross-collaboration among faculty and reinvigorate a culture of academic engagement, prioritizing the strengthening of research infrastructure and the translational pipeline. The Chief should inspire the Section to build on existing SPORE and P01 grants, foster bench-to-bedside collaborations, and expand impactful clinical trials across the network, including community sites.

Develop, recruit, and retain diverse faculty, staff, and trainees

Professional development of all levels of personnel should be top of mind for the Section Chief. The Chief must identify and implement real pathways for growth and build structures for formal mentoring for all members of the division, especially junior faculty and fellows. They should also create transparent, equitable processes for promotion and career advancement and champion junior faculty by protecting research time and supporting physician-scientist pathways. The Chief will promote the recruitment of high-caliber physician-scientists, research scientists, and staff while mindfully optimizing the composition of the division and its clinical needs. In concert with research leaders in the division and at the cancer center, the Chief will address retention issues proactively and strategically, recognizing that the best retention efforts are enabling faculty to feel valued, supported, and professionally satisfied.

Champion the interests and culture of the Section of Medical Oncology and Hematology

Given the complex and matrixed environment of YSM, YCC, and YNHH, the Section needs a champion who will advocate for its efforts across the enterprise. This leader must galvanize and inspire continued success across all missions, serving as a champion for faculty, staff, and fellows, connecting their work to the broader missions of the department, school, and cancer center. The Section enjoys great collegiality and a collaborative spirit. The Chief will set cultural expectations, establish and maintain trust through a high level of transparency and communication, and have an unwavering commitment to inclusive excellence and decision-making. This leader will maintain high standards with respect to professionalism and integrity. With the goal of breaking down siloes and operational barriers, the Chief will drive efforts to foster community across the Section and unite historically separate groups, like hematology, under a cohesive vision.

Foster excellent educational opportunities to train the next generation of medical oncologists and hematologists

The Section offers subspecialty fellowship training in medical oncology and/or hematology in a program that is large and prestigious, attracting nationally competitive trainees. Fellows obtain extensive clinical experience and have an opportunity for in-depth study in clinical, basic, or translational research. The combination of training in patient care and research provides physicians with strong clinical skills and the foundation for a successful career in academics or clinical practice. The Section Chief will continue to elevate the fellowship to its top-tier status, which includes enhancing mentorship structures and investing in education initiatives that attract and retain top talent. The Chief will be mindful of the pressure between clinical productivity and the training mission.

QUALIFICATIONS AND CHARACTERISTICS

The successful candidate must have: an MD, DO, MD/PhD, or equivalent clinical doctoral degree with board-certification; significant experience as a clinical leader at an academic medical center; an

outstanding record of scholarly accomplishment and national recognition in medical oncology or hematology; a demonstrated track record of extramurally funded research for clinical investigation, translational research, basic laboratory studies, and/or health services research; a strong commitment to education across a broad spectrum of learners; a record commensurate with appointment to the rank of professor at Yale School of Medicine; and be eligible for licensure in Connecticut.

The Section Chief will also possess the following qualities and attributes:

- An ability to foster a highly collaborative academic environment
- A track record of partnering with a broad set of stakeholders
- Exceptional leadership skills, with the proven ability to foster a spirit of unity and collaboration
- High emotional intelligence, strong communication, and the ability to build and maintain trust across a matrixed organization
- Outstanding interpersonal skills with a variety of stakeholders, including faculty, administration, and trainees, as well as medical, nursing, and technical staff
- Excellent oral and written communication skills
- Experience in working within a highly matrixed environment
- Proven effectiveness in a complex system of distributed leadership
- Demonstrated commitment to fostering a culture of excellence, equity, and innovation
- A strong advocate and facile negotiator in a complex, dynamic environment
- A detailed and nuanced understanding of both research and clinical practice in oncology and hematology
- A respectful, inclusive, compassionate, and supportive management style
- Demonstrated experience in recruiting and retaining top faculty and fellows through active mentorship
- Exceptional planning and organizational skills, superb follow-through, and timely task completion
- A record of complex financial, budgeting, and resource management skills
- Personal qualities which include kindness, humility, inclusivity, creativity, flexibility, tenacity, courage, a sense of humor, optimism, and unquestionable integrity

APPLICATIONS, INQUIRIES, AND NOMINATIONS

Screening of complete applications will begin immediately and continue until the completion of the search process. Inquiries, nominations, referrals, and CVs with cover letters should be sent via the Isaacson, Miller website: <https://www.imsearch.com/open-searches/yale-school-medicine/chief-hematology-oncology>.

Ariannah Mirick, Managing Partner
Jane McInerney, Managing Associate
Madeleine Ruth, Managing Search Coordinator
Isaacson, Miller

The final candidate, upon acceptance of a contingent offer of employment/faculty appointment, may be required to disclose whether they are, or have been, the subject of any disciplinary proceeding (investigation, hearing, etc.) at previous institutions or employers, and may also be subject to a background screening. Candidates who materially misrepresent information on their resume or other application materials are ineligible for hire/appointment. Final candidates may also be required to sign a release to allow Yale to solicit information regarding any substantiated conduct violations from current and/or past employers.

Yale is an equal opportunity employer: <https://your.yale.edu/policies-procedures/policies/9000-yale-university-policy-against-discrimination-and-harassment#9000.1> Yale values diversity among its students, staff, and faculty and welcomes applications from candidates with a broad range of backgrounds and perspectives. Title IX of the Education Amendments of 1972 protects people from sex discrimination in educational programs and activities at institutions that receive federal financial assistance. Questions regarding Title IX may be referred to the University's Title IX Coordinator, at TitleIX@yale.edu, or to the U.S. Department of Education, Office for Civil Rights, 8th Floor, Five Post Office Square, Boston MA 02109-3921. Telephone: 617.289.0111, Fax: 617.289.0150, TDD: 800.877.8339, or Email: ocr.boston@ed.gov.

This document has been prepared based on the information provided by Yale School of Medicine. The material presented in this leadership profile should be relied on for informational purposes only. While every effort has been made to ensure the accuracy of this information, the original source documents and information provided by Yale School of Medicine would supersede any conflicting information in this document.

APPENDIX

Yale School of Medicine

Founded in 1810, [Yale School of Medicine](#) (YSM) is the sixth oldest medical school in the country and a leading institution for biomedical research, education, and advanced clinical care. YSM's standing rests on its impressive history of attracting top-tier scientists in both the basic science and clinical departments, a prized medical education system that prioritizes self-directed learning, and a close partnership with the Yale New Haven Health System (YNHHS) for clinical care. YSM currently ranks third among medical schools receiving funds from the National Institutes of Health (NIH). More than 1,700 Yale physicians provide care to patients from across the region and around the world.

YSM educates and nurtures creative future leaders in medicine, public health, and biomedical science, promoting curiosity and critical inquiry in an inclusive environment enriched by diversity. A total of 1,840 students are currently enrolled at YSM, including 396 medical students, 153 MD/PhD students, and 457 PhD students. YSM houses 5,419 faculty and 1,853 postdoctoral fellows and associates in 34 [academic departments](#). There are 11 basic science departments and 18 clinical departments. Yale has 67 faculty members belonging to the National Academy of Sciences, 60 members belonging to the National Academy of Medicine or both academies, seven Howard Hughes Medical Institute Investigators, four Lasker Award recipients, and [three](#) Nobel Laureates.

YSM's core research resources are built around the newest technologies such as state-of-the-art tools for genomics and proteomics, including whole-genome sequencing and mass spectrometry; high-resolution imaging and image analysis at every scale, including cryoelectron microscopy, cryoelectron tomography, and the only focused ion beam-scanning electron microscope in the region; high-throughput screening, including RNAi and chemical screens; and construction and analysis of animal models of disease.

The university leadership's commitment to enhancing science at Yale, coupled with the close proximity of YSM to the main campus and the collaborative, collegial environment for research, galvanizes interdisciplinary research across the university. Funding for research at YSM has increased from \$539.6M in 2012 to \$955.9M in 2024 with \$597.9M awarded from NIH, a portion of which represents 24 center and program grants. Approximately two-thirds of total sponsored research expenditures are from clinical departments, with the remaining third coming from the basic sciences.

School of Medicine Leadership

Yale School of Medicine is led by Dean Nancy J. Brown, MD, who reports to the president of the university. Dean Brown joined the campus community in 2020 from Vanderbilt University Medical Center where she was the chair of the Vanderbilt Department of Medicine and physician-in-chief of Vanderbilt University Hospital. From 2006-2010, she served as the Associate Dean for Clinical and Translational Scientist Development and established an institutional infrastructure to support physician-scientists in the

transition to independence. Dr. Brown is a fellow in the American Association for the Advancement of Science and a member of the American Society for Clinical Investigation, the American Association of Physicians, the National Academy of Medicine, and the American Academy of Arts and Sciences. Under her leadership, YSM is formulating ambitious priorities and making critical investments.

Yale New Haven Health

[Yale New Haven Health](#) (YNHHS) is Connecticut's leading healthcare system and the largest private employer in the state, with hospitals in Bridgeport, Greenwich, Milford, New Haven, and New London in Connecticut and a hospital in Westerly, Rhode Island. Among those hospitals is Yale New Haven Hospital (YNHH), the top-ranked hospital in Connecticut by *U.S. News and World Report* and nationally ranked in eleven adult and five pediatric specialties. YNHH has over 1,500 beds and 4,500 university and community physicians across more than 100 specialties. YNHH has received Magnet designation from the American Nurses Credentialing Center and is the primary teaching hospital for YSM. In FY23, YNHH generated \$4.41 billion in net revenue across 1.7 million outpatient encounters and 85,000 inpatient discharges. Total revenue to YNHHS was \$6.56 billion.

In 2022, YNHH broke ground on the Adams Neuroscience Center, a 505,000-square-foot project that includes two new patient facilities focused on innovative patient care and research. The project includes 201 inpatient beds for patients seeking innovative care from movement disorders to neuro-regeneration, and the clinical presence includes neurosurgery, radiology, and neurology.

YNHHS is led by Chief Executive Officer Christopher O'Connor and President Pamela Sutton-Wallace. O'Connor joined the health system in 2012 as executive vice president and chief operating officer and was appointed president in 2020 and chief executive officer in 2022. Previously, O'Connor was president and CEO of the Saint Raphael Healthcare System and the Hospital of Saint Raphael, serving in that position until Saint Raphael's successful integration into Yale New Haven Hospital in September 2012. Sutton-Wallace joined Yale New Haven Health in July 2022 as chief operating officer and was tasked with helping guide the Health System out of the pandemic and into its envisioned future as an academic health system. She was promoted to president in 2024.

Yale New Haven Hospital, the flagship hospital of YNHHS, is led by President Katherine Heilpern. Dr. Heilpern joined the YNHH system in 2024, and previously served as Senior Vice President and Chief Operating Officer of New York Presbyterian Hospital/Weill Cornell, where she led the Weill Cornell Division during the apex of COVID-19 infections in New York City.

The Department of Internal Medicine

The [Department of Internal Medicine](#) is the largest department at Yale School of Medicine (YSM) and the most extensive clinical service at Yale New Haven Hospital (YNNH). Its clinical practice generates nearly 50% of the Department's operating revenue—approximately \$200 million—and represents almost a quarter of YSM's clinical departments. Clinical activities are primarily based at YNNH and the Yale Physician Building, with additional services provided at the Veterans Affairs Connecticut Health Care System in West Haven. The Department's ambulatory network spans 46 sites across Connecticut, ensuring broad access to Yale's internal medicine and specialty care.

The Department comprises more than 1,200 faculty, including members of the National Academy of Medicine, National Academy of Sciences, and other prestigious organizations. Over the past decade, it has seen significant growth in both clinical and research missions, now operating with a budget exceeding \$400M. Organized into 11 [academic sections](#), the Department has achieved national and international prominence through its clinical, educational, and research activities. Most sections are housed in The Anlyan Center, a state-of-the-art facility that supports research and education, alongside distinctive programs and research centers dedicated to advancing medicine.

Internal Medicine is Yale's largest research unit, securing \$217M in sponsored funding and ranking #12 in NIH funding for FY24, according to the Blue Ridge Institute for Medical Research. More than two-thirds of faculty actively engage in research, spanning clinical outcomes, epidemiology, translational studies, and basic science. Embedded within Yale's collaborative scientific environment, the Department fosters interdisciplinary and translational research opportunities that drive innovation and discovery.

As the largest department at YSM and YNNH, Internal Medicine plays a central role in education. It supports pre-clinical courses, inpatient and primary care clerkships, sub-internships, and numerous electives for students. Postgraduate training includes four residency programs with over 230 residents and 13 ACGME-approved fellowship programs, many funded by NIH training grants. Fellows train across major subspecialties at YNNH, VA Connecticut, and affiliated hospitals, benefiting from diverse clinical experiences and robust research opportunities. The Department also contributes over 800 annual contact hours of educational support to nine affiliated hospitals through lectures, seminars, and bedside rounds.

Yale Cancer Center and Smilow Cancer Hospital

The [Yale Cancer Center](#) (YCC) is a collaboration between the Yale School of Medicine and [Smilow Cancer Hospital](#). YCC, an NCI-designated Comprehensive Cancer Center since 1974, is the only such center in Connecticut and a leader in cancer research, education, and clinical care. Closely integrated with Smilow Cancer Hospital at Yale New Haven, YCC combines world-class science with multidisciplinary, patient-centered care. Smilow is the largest provider of cancer services in the state, treating nearly 48% of the state's cancer patients, offering 13 disease-specific centers of excellence and a network of 15 care

locations across Connecticut and Rhode Island. With more than 300 faculty investigators, robust translational research programs, and over 300 active clinical trials—including a dedicated Phase I unit—YCC drives innovation from bench to bedside. Supported by nearly \$100M in annual research funding, including \$29M from NCI, YCC and Smilow Cancer Hospital exist in a collaborative academic environment and are committed to advancing discoveries that improve outcomes for patients locally and globally.

Research endeavors at YCC are focused through seven research programs that include faculty members and researchers from a variety of disciplines: Developmental Therapeutics; Genomics, Genetics & Epigenetics; Cancer Immunology; Cancer Microbiology; Cancer Signaling Networks; Cancer Prevention & Control; and Radiobiology & Radiotherapy. These research programs encompass the activities of a group of investigators from different disciplines and academic departments who share common scientific interests and goals and participate in competitively funded research. These research programs are supported by five transdisciplinary centers, including the Center for Molecular and Cellular Oncology (CMCO) and the Yale Center for Immuno-Oncology (YCIO), the Yale Cancer Biology Institute, the Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center and the DeLuca Center for Innovation in Hematology Research. These programs foster collaboration among basic scientists and clinicians to accelerate translational research. Clinical trials are available for all disease areas, including early-phase studies for advanced cancers, giving patients access to cutting-edge therapies. Yale investigators have pioneered breakthroughs in chemotherapy and targeted treatments, and continue to lead studies on HER-2 positive breast cancer, brain tumors, and immunotherapy. Research efforts are bolstered by shared resources in genomics, biostatistics, and tissue services, as well as NIH-funded Cancer Center Support Grant.

Education is central to YCC's mission, with programs spanning high school through junior faculty. The Cancer Research Training and Education Coordination (CRTEC) office oversees initiatives such as the Discovery to Cure Internship for high school students, the ACS Center for Innovation in Cancer Research Training for undergraduates, and post-baccalaureate fellowships. Graduate and postdoctoral trainees benefit from specialized programs like the Yale Cancer Biology Training Program and the Cancer Prevention and Control Training Program, which provide rigorous research experience, mentorship, and professional development. Medical students can participate in clinical fellowships at Smilow Cancer Hospital, while residents and clinical fellows receive hands-on training in oncology care and research. Annual events like the YCC Trainee Colloquium foster collaboration and showcase emerging research.

Yale Cancer Center and Smilow Cancer Hospital exemplify an integrated model of care, research, and education. Their collaborative structure ensures that discoveries in the lab translate quickly to patient care, while clinical insights inform ongoing research. This synergy supports YCC's role as a national leader in cancer prevention, treatment innovation, and workforce development. By combining comprehensive clinical services, pioneering research programs, and robust educational opportunities, YCC and Smilow advance the fight against cancer locally and globally, improving outcomes and shaping the future of oncology.